News BMS announces positive Reblozyl phase 3 results for MDS Bristol Myers Squibb has announced positive topline results from its
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.
